S

Splisense

13 employees

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Pharmaceutical
Life Science

Date founded

2017

Funding rounds raised

Total raised

$29M

from 3 investors over 3 rounds

S

Splisense raised $29M on May 13, 2021

Investors: Integra Holdings and OrbiMed Advisors

S

Splisense raised undisclosed on January 1, 2016

Investors: Integra Holdings

FAQ